FIGR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Figure Technology Solutions Inc (FIGR) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows mixed signals, with no significant positive catalysts, neutral technical indicators, and a lack of strong trading sentiment. Additionally, analysts have conflicting views, and the company's financial performance shows no significant growth momentum. Holding off on investing in this stock might be prudent given the current data.
The MACD is positive at 0.589, indicating mild bullish momentum, but it is contracting. The RSI is neutral at 61.567, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key resistance levels are at $36.383 and $38.056, while support levels are at $30.966 and $29.293. Overall, the technical indicators are neutral, providing no strong buy signal.
Goldman Sachs recently raised the price target to $44 and maintains a Buy rating, citing strong March and Q1 preliminary operating data and long-term growth potential. Expanding partnerships and product development are also highlighted as positive factors.
Morpheus Research has issued a highly critical report, questioning the company's blockchain claims and suggesting it is primarily a HELOC lender with aggressive underwriting and mounting competition. Insider and hedge fund trading trends are neutral, and there is no recent news or significant congress trading data to support positive momentum. Analysts have also been lowering price targets consistently.
In Q4 2025, revenue was flat year-over-year at $159.91M. Net income increased slightly to $23.03M, and EPS rose 12.5% to $0.09. However, gross margin remained stagnant at 0%. The financial performance shows no significant growth trends, which is concerning for a long-term investment.
Analyst ratings are mixed. While firms like Goldman Sachs and Bernstein maintain Buy or Outperform ratings with higher price targets, others like Morpheus Research and BofA have issued critical views or downgraded the stock. Price targets have been consistently revised downward, reflecting cautious sentiment.
